Ovarian hyperstimulation syndrome (OHSS)
Conditions
Interventions
group IA (PCO or PCOS patients):Group IA patients will be administered Fraxiparine 4100 IU subcutaneous once daily with COH (controlled ovarian hyperstimulation) start until pregnancy was confirmed or
group IB (PCO or PCOS patients):Groups IB will be injected by placebo subcutaneous once daily with COH start until pregnancy was confirmed or not.
group IC (matched controls for groups IA and IB):No intervention (matched controls)
groupIIA (high risky for OHSS):Group IIA will be administered Fraxiparine 4100 IU subcutaneous once daily which starts on HCG day until pregnancy was confirmed or not.
groupIIB (high risky for OHSS):Group IIB will be injected by placebo subcutaneous once daily which starts on HCG day until pregnancy was confirmed or not.
group IC (matched controls for groups IIA and IIB):No intervention (matched controls)
group IIIA (severe OHSS patients):Group IIIA patients were administered Fraxiparine 4100 IU subcutaneous once diagnosed until recovery.
group IIIB (severe OHSS patients):Group IIIA patients were administered placebo subcutaneous once diagnosed until recovery.
Sponsors
Women’s Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
Female
Age
23 Years to 38 Years
Inclusion criteria
Inclusion criteria: Patients will be selected when they fulfill the following criteria: 1. Patients aged between 23-38 years; 2. No previous history of any medication for induction of ovulation in the 2 months preceding enrollment in the study; 3. Study participants will be counseled, and an informed consent will be obtained.
Exclusion criteria
Exclusion criteria: 1. Patients with endocrinological disorders in the form of thyroid hypo/hyper-function, diabetes mellitus, hyperprolactinemia and Cushing syndrome as determined from history, examination and laboratory investigations; 2. Failure to obtain an informed consent from the patient; 3. Induction of ovulation in the 2 months preceding the enrollment in the clinical trial; 4. Day3 FSH >=10 mIU/ml; 5. Patients with contraindication for Heparin therapy as coagulopathy and chronic liver disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| vascular endothelial growth factor (VEGF);tissue factor (TF);tissue factor pathway inhibitor (TFPI); | — |
Countries
China
Contacts
Public ContactHe-Feng Huang
Outcome results
None listed